This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Sign In   |   Register
News: Publications

Commentary: Novel therapeutics specific to lipoprotein(a)

Friday 26 April 2019   (0 Comments)
Share |
Novel therapeutics specific to lipoprotein(a) are now available and offer the means to test the ‘lipoprotein(a) hypothesis.’. However, it is essential to clinical trial design to estimate how much lipoprotein(a) lowering is required for meaningful clinical benefit in a representative high- risk patient population. A recent Mendelian randomization analysis provides new insights highly pertinent to this question.

To the commentary by Jane K. Stock>>

Membership Software Powered by YourMembership  ::  Legal